https://www.selleckchem.com/pr....oducts/tuvusertib.ht
Meta-analyses of randomised trials of paclitaxel-coated peripheral devices found an association with worse long-term survival. We assessed long-term mortality in patients treated with drug-coated devices insured by Medicare Advantage (MA), an alternative to traditional Medicare that represents 30% of the Medicare eligible population. Patients treated with or without drug-coated devices for femoropopliteal artery revascularisation from 4/2015-12/2017 were studied using Optum's De-identified Clinformatics® Datamart Database. Mortal
Gefällt mir
Kommentar
Teilen
